Rejuvenate Bio to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

2024-04-22

基因疗法临床研究

SAN DIEGO--(BUSINESS WIRE)-- Rejuvenate Bio, a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. “We’re excited to share data at ASGCT 2024 on our RJB-0402 gene therapy which targets key disease-mediating pathways in arrhythmogenic cardiomyopathy (ACM),” said Noah Davidsohn, PhD., Chief Scientific Officer at Rejuvenate Bio. “ACM is an inherited disease caused by mutations in one of several genes encoding desmosomal proteins, and there is an urgent need for better treatment options. If our approach proves effective to treat ACM, it would have a dramatic impact on the profound burden this disease has on patients and their families.” Title: AAV FGF21 Gene Therapy as a Variant Agnostic Treatment for Arrhythmogenic Cardiomyopathy Session Type: In-Person Oral Presentation Session Title: Next Generation Gene & Cell Therapies for Heart, Lung, and Kidney Diseases Abstract Number: 79 Location: Room 314-317 Session Date/Time: Wednesday May 8, 2024 1:30 PM - 3:15 PM Abstracts will be released to the public on April 22, 2024, at 4:30 p.m. ET at . The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 8, 2024. A copy of the presentation will be available at once the presentation concludes. About Rejuvenate Bio Rejuvenate Bio is a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases. Rejuvenate Bio has built a gene therapy pipeline with huge potential in chronic disease by utilizing clinically validated gene targets and a delivery approach that ensures well tolerated, durable expression. Founded on scientific research developed at the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed groundbreaking therapies to treat chronic age-related disease in both humans and animals. The company is headquartered in San Diego, CA. For more information, visit .

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构